Aspergillus terreus: How inoculum size and host characteristics affect its virulence

Journal of Infectious Diseases

Volumn 205, Issue 8, 2012, Pages 1192-1194

  Lass Flörl, Cornelia ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCAN; CITREOVIRIDIN; CITRININ; CORTICOSTEROID; CYCLOSPORIN A; CYTOCHALASIN E; CYTOKINE; EMODIN; GEODIN; GLIOTOXIN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 22; MEVINOLIN; MYCOTOXIN; PATULIN; TERRETONIN; TERRITREMS; UNCLASSIFIED DRUG;

ASPERGILLUS TERREUS; CELL ACTIVITY; CELL DEGENERATION; CELL VIABILITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; FUNGAL CELL; FUNGAL GENE; FUNGAL STRUCTURES; FUNGAL VIRULENCE; FUNGUS GROWTH; FUNGUS TRANSMISSION; GENE CONTROL; GERMINATION; HOST PATHOGEN INTERACTION; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; INOCULATION; LIVER CELL; LIVER FATTY DEGENERATION; LIVER TOXICITY; LUNG ASPERGILLOSIS; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SPECIES DIFFERENCE; TOXIN SYNTHESIS;

ANIMALS; ASPERGILLUS; FEMALE; LIVER DISEASES; PULMONARY ASPERGILLOSIS; SPORES, FUNGAL;

EID: 84859015827     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis185     Document Type: Note

References (19)

1. Perkhofer S, Lass-Flörl C, Hell M, et al. The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients. Int J Antimicrob Agents 2010; 36:531-6.
2. Lass-Flörl C, Griff K, Mayr A, et al. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol 2005; 131:201-7.
3. Lass-Flörl C, Grif K, Kontoyiannis DP. Molecular typing of Aspergillus terreus isolates collected in Houston, Texas, and Innsbruck, Austria: evidence of great genetic diversity. J Clin Microbiol 2007; 45: 2686-90.
4. Steinbach WJ, Benjamin DK Jr, Kontoyiannis DP, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004; 39:192-8.
5. Balajee SA. Aspergillus terreus complex. Med Mycol 2009; 47(Suppl 1):S42-6.
6. Deak E, Nelson M, Hernández-Rodríguez Y, et al. Aspergillus terreus accessory conidia are multinucleated, hyperpolarizing structures that display differential dectin staining and can induce heightened inflammatory responses in a pulmonary model of aspergillosis. Virulence 2011; 2:200-7.
7. Deak E, Wilson SD, White E, Carr JH, Balajee SA. Aspergillus terreus accessory conidia are unique in surface architecture, cell wall composition and germination kinetics. PLoS One 2009; 4:e7673.
8. Lass-Flörl C, Alastruey-Izquierdo A, Cuenca- Estrella M, Perkhofer S, Rodriguez-Tudela JL. In vitro activities of various antifungal drugs against Aspergillus terreus: global assessment using the methodology of the European committee on antimicrobial susceptibility testing. Antimicrob Agents Chemother 2009; 53:794-5.
9. Blum G, Perkhofer S, Haas H, et al. Potential basis for amphotericin B resistance in Aspergillus terreus. Antimicrob Agents Chemother 2008; 52:1553-5.
10. Walsh TJ, Petraitis V, Petraitiene R, et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis 2003; 188:305-19.
11. Dixon DM, Polak A, Walsh TJ. Fungus dosedependent primary pulmonary aspergillosis in immunosuppressed mice. Infect Immun 1989; 57:1452-6.
12. Sheppard DC, Rieg G, Chiang LY, Filler SG, Edwards JE Jr, Ibrahim AS. Novel inhalational murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2004; 48:1908-11.
13. Rüping MJ, Gerlach S, Fischer G, et al. Environmental and clinical epidemiology of Aspergillus terreus: data from a prospective surveillance study. J Hosp Infect 2011; 78:226-30.
14. Stephens-Romero SD, Mednick AJ, Feldmesser M. The pathogenesis of fatal outcome in murine pulmonary aspergillosis depends on the neutrophil depletion strategy. Infect Immun 2005; 73:114-25.
15. Vyas JM. The duality of Aspergillus terreus: differential immune responses to distinct conidia. Virulence 2011; 2:181-4.
16. Clemons KV, Grunig G, Sobel RA, Mirels LF, Rennick DM, Stevens DA. Role of IL-10 in invasive aspergillosis: increased resistance of IL-10 gene knockout mice to lethal systemic aspergillosis. Clin Exp Immunol 2000; 122: 186-91.
17. Zelante T, Bozza S, De Luca A, et al. Th17 cells in the setting of Aspergillus infection and pathology. Med Mycol 2009; 47(Suppl 1): S162-9.
18. Samson RA, Peterson SW, Frisvad JC, Varga J. New species in Aspergillus section Terrei. Stud Mycol 2011; 69:39-55.
19. Speth C, Kupfahl C, Pfaller K, et al. Gliotoxin as putative virulence factor and immunotherapeutic target in a cell culture model of cerebral aspergillosis. Mol Immunol 2011; 48:2122-9.